EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Multizentrische StudieOpen Access · CC BY-NC-ND 4.0

Glycan shielding enables TCR-sufficient allogeneic CAR-T therapy

Zeguang Wu, Jinhong Shi, Qiezhong Lamao, Yuanyuan Qiu, Jinxin Yang, Yang Liu, Feifei Liang, Xue Sun, Wei Tang, Changya Chen, Qingming Yang, Chunmeng Wang und 22 weitere

Cell · 2025-10 · 188 (22) · 6317-6334.e21

DOI: 10.1016/j.cell.2025.07.046 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Cell, 2025-10. Verfasst von Zeguang Wu und 33 weiteren Autor:innen. Beteiligte Einrichtung: Biomedical Pioneering Innovation Center, Peking-Tsinghua Center for Life Sciences, Peking University Genome Editing Research Center, State Key Labora…. Hauptthemen laut MEDLINE: Immunotherapy, Adoptive, Polysaccharides, Receptors, Antigen, T-Cell, Receptors, Chimeric Antigen. Die Arbeit wurde bisher 44-mal zitiert (Crossref) und nennt 68 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Chinese Academy of Medical Sciences, Chinese Academy of Medical Sciences Initiative for Innovative Medicine, Ministry of Science and Technology of the People's Republic of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Despite the success of autologous chimeric antigen receptor (CAR)-T cell therapy, achieving persistence and avoiding rejection in allogeneic settings remains challenging. We showed that signal peptide peptidase-like 3 (SPPL3) deletion enabled glycan-mediated immune evasion in primary T cells. SPPL3 deletion modified glycan profiles on T cells, restricted ligand accessibility, and reduced allogeneic immunity without compromising the functionality of anti-CD19 CAR molecules. In a phase I clinical trial, SPPL3-null, T cell receptor (TCR)-deficient anti-CD19 allogeneic CAR-T cells reached the safety primary endpoint, with grade 3 or higher cytokine release syndrome (CRS) observed in 3 out of 9 patients with relapsed/refractory B cell non-Hodgkin lymphoma (B-NHL) (ClinicalTrials.gov: NCT06014073). Reverse translational research highlighted the pivotal role of TCR in sustaining T cell persistence. We therefore evaluated the safety of SPPL3-null, TCR-sufficient CAR-T therapy on three patients with lymphoma or leukemia for compassionate care and observed no clinical signs of graft-versus-host disease. Our findings suggest glycan shielding by SPPL3 deletion is a promising direction for optimizing universal CAR-T therapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immunotherapy, AdoptivePolysaccharidesReceptors, Antigen, T-CellReceptors, Chimeric AntigenAdultFemaleHumansMaleMiddle AgedAntigens, CD19Graft vs Host DiseaseT-Lymphocytes

Stichwörter der Autor:innen

CAR-T cellactivation-induced cell deathallogeneic immunitygenome-wide CRISPR screensglycangraft-versus-host diseasehost-versus-graftnatural killer cellrelapsed/refractory B-NHLsignal peptide peptidase-like 3

Substanzen

Antigens, CD19PolysaccharidesReceptors, Antigen, T-CellReceptors, Chimeric Antigen

Autor:innen und Institutionen

  • Biomedical Pioneering Innovation Center, Peking-Tsinghua Center for Life Sciences, Peking University Genome Editing Research Center, State Key Laboratory of Gene Function and Modulation Research, School of Life Sciences…
  • School of Medicine, Nankai University, Tianjin 300071, China; Department of Bio-Therapeutic, the First Medical Center, Chinese PLA General Hospital, Beijing 100039, China.
  • Department of Bio-Therapeutic, the First Medical Center, Chinese PLA General Hospital, Beijing 100039, China.
  • EdiGene Inc., Life Science Park, Changping District, Beijing 102206, China.
  • School of Pharmacy, University of Wisconsin-Madison, Madison, WI 53705, USA; First School of Clinical Medicine, Peking University, Beijing 100871, China.
  • State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sc…

Förderung

  • Chinese Academy of Medical Sciences
  • Chinese Academy of Medical Sciences Initiative for Innovative Medicine
  • Ministry of Science and Technology of the People's Republic of China
  • State Key Laboratory for Diagnosis and Treatment of Infectious Diseases
  • Center for Life Sciences
  • Changping Laboratory
  • National Natural Science Foundation of China
  • National Key Research and Development Program of China

Zitieren

APA

Wu, Z., Shi, J., Lamao, Q., Qiu, Y., Yang, J., Liu, Y., Liang, F., Sun, X., Tang, W., Chen, C., Yang, Q., Wang, C., Li, Z., Zhang, H., Yang, Z., Zhang, Y., Yi, Y., Zheng, X., Sun, Y., …, & Wei, W. (2025). Glycan shielding enables TCR-sufficient allogeneic CAR-T therapy. Cell, 188(22), 6317-6334.e21. https://doi.org/10.1016/j.cell.2025.07.046

Vancouver

Wu Z, Shi J, Lamao Q, Qiu Y, Yang J, Liu Y, et al. Glycan shielding enables TCR-sufficient allogeneic CAR-T therapy. Cell. 2025;188(22):6317-6334.e21. doi:10.1016/j.cell.2025.07.046

BibTeX
@article{Wu2025,
  author = {Wu, Zeguang and Shi, Jinhong and Lamao, Qiezhong and Qiu, Yuanyuan and Yang, Jinxin and Liu, Yang and Liang, Feifei and Sun, Xue and Tang, Wei and Chen, Changya and Yang, Qingming and Wang, Chunmeng and Li, Zhifang and Zhang, Haixia and Yang, Zhonghan and Zhang, Yunyi and Yi, Yuting and Zheng, Xufen and Sun, Yu and Ma, Kuiying and Yu, Lingling and Yang, Huihui and Wang, Zhaoxuan and Zheng, Wenjuan and Yang, Ling and Zhang, Zhixuan and Zhang, Yongjian and Wu, Zhiqiang and Wang, Yao and Wong, Catherine C L and Jin, Ming and Yuan, Pengfei and Han, Weidong and Wei, Wensheng},
  title = {Glycan shielding enables TCR-sufficient allogeneic CAR-T therapy},
  journal = {Cell},
  year = {2025},
  volume = {188},
  number = {22},
  pages = {6317--6334.e21},
  doi = {10.1016/j.cell.2025.07.046}
}
Kostenlos starten →